1S90.F Seres Therapeutics, Inc.
- Market cap
- EUR 13.9M
- P/E
- -
- P/B
- 0.87x
- ROE
- -197.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1S90.F undervalued?
Graham numberThe Graham number of Seres Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Seres Therapeutics, Inc. fundamental analysis
No fundamental analysis for Seres Therapeutics, Inc. yet.
Seres Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also dev…
Full company profileSeres Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Seres Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 145M | 0.00 | 0.00 | 0.00 | 789K | 0.00 |
| Gross Profit | - | 0.00 | 0.00 | -3.53M | -5.76M | 0.00 |
| Operating Income | -64.5M | -180M | -195M | -121M | -94.0M | -62.4M |
| EBITDA | - | -171M | -181M | -120M | 9.83M | -59.9M |
| Net Income | -65.6M | -250M | -114M | 136K | 5.70M | -42.2M |
| EPS | -14 | -40 | -17 | 0.02 | 0.60 | -4.19 |
| Balance Sheet | ||||||
| Total Assets | 355M | 349M | 359M | 140M | 138M | 65.9M |
| Total Liabilities | 223M | 338M | 403M | 126M | 94.0M | 44.5M |
| Shareholders' Equity | 132M | 10.8M | -44.9M | 13.8M | 44.2M | 21.4M |
| Cash & Short-term Investments | 180M | 163M | 128M | 30.8M | 45.8M | 17.5M |
| Cash Flow | ||||||
| Operating Cash Flow | 6.69M | -229M | -117M | -149M | 1.12M | -65.6M |
| Capital Expenditure | 9.57M | 9.82M | 7.98M | 380K | 252K | 0.00 |
| Free Cash Flow | -2.88M | -239M | -125M | -149M | 865K | -65.6M |
| Ratios | ||||||
| ROE | -49.9% | -2,319.9% | - | 1.0% | 12.9% | -197.4% |
| ROA | -18.5% | -71.7% | -31.7% | 0.1% | 4.1% | -64.0% |
| Net Profit Margin | -45.2% | - | - | - | 721.9% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Seres Therapeutics, Inc. dividends
Seres Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Apr 22, 2025.
Who owns Seres Therapeutics, Inc.
- Insiders 11.49%
- Institutions 22.99%
- Public & others 65.53%
- Shares outstanding 10.2M
- Free float 8.74M
Seres Therapeutics, Inc. company profile
- Company name
- Seres Therapeutics, Inc.
- Ticker
- 1S90.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 66
- Fiscal year end
- December
- Address
- 101 Cambridgepark Drive, Cambridge, MA, United States, 02140
- Phone
- 617 945 9626
- Website
- serestherapeutics.com
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics, Inc. management
8- Mr. Richard N. Kender B.S., M.B.A.Interim CEO & Executive Chair · born 1956
- Dr. Matthew R. Henn Ph.D.President & Chief Scientific Officer · born 1975
- Ms. Marella Thorell C.P.A.Executive VP, CFO & Treasurer · born 1967
- Mr. Thomas J. DesRosier Esq., J.D.Executive VP, Chief Legal Officer & Secretary · born 1955
- Ms. Kelly Brady M.S.Executive VP & COO · born 1984
- Mr. Chris McChalicherExecutive VP & CTO
- Dr. Dennis M. Walling M.D.Senior VP of Clinical Development & Head of Clinical Research
- Ms. Ann KurowskiSenior Vice President of Regulatory Affairs